Seer, Inc. (SEER) Stock

Seer, Inc. (SEER) is a Technology stock trading at $2.02 (as of 2026-08-20), with a market capitalization of $111.85M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

I can’t produce a compliant description yet because the SEC 10‑K “Business” (Item 1) text for Seer, Inc. wasn’t provided. Please paste the Item 1 “Business” section (or a link plus the relevant excerpt) and I’ll return a 1–2 sentence, ~45‑word JSON description based only on that text.

Understand Seer, Inc.: how it makes money

Seer, Inc. develops and commercializes Proteograph proteomics solutions (consumables, automation instrumentation, and software) that researchers and biopharma customers use to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials, earning money from product and service sales.

SEER monetizes an integrated proteomics stack, Proteograph Product Suite, meaning its profit model depends on converting customer adoption into ongoing product and service revenue linked to instruments, consumables, and software.

Revenue by segment (latest quarter)
Product$0.0B
Service$0.0B
Other$0.0B

Business quality (Weak): The company reports a Proteograph platform with measurable adoption and scientific validation, but the latest quarter shows 0.0B revenue and a deeply negative operating margin, indicating financial losses before scale.

Bull case

  • Installed base is building: The company reports Installed Base Instruments of 82.0 (count), which indicates customers have instruments in use.
  • Scientific validation supports the platform: Seer reports 84.0 peer-reviewed publications, preprints, and reviews validating the Proteograph Product Suite.

Bear case

  • No reported top line this quarter: For the 2026-03-31 quarter, Product Revenue is 0.0B and Service Revenue is 0.0B, with Other Revenue also at 0.0B.
  • Operating losses are large: The latest quarter shows an operating margin of -617.8%, reflecting substantial operating costs relative to revenue.
Valuation — source: SEC EDGAR (first-party)
Price$2.02
Market Cap$111.85M
Price / Book0.50
Price / Sales8.73
FCF Yield-82.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$16.58M
Net Margin-444.0%
Revenue Growth (YoY)17.0%
FCF Growth (YoY)-6.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.40 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSOFTBANK GROUP CORP. ($8.63M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOOmid C. Farokhzad
Employees134
CountryUS
IPO Date2020-12-04

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Cytek Biosciences, Inc. (CTKB)
  • Pacific Biosciences of California, Inc. (PACB)
  • Harvard Bioscience, Inc. (HBIO)
  • Quanterix Corporation (QTRX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Rapid Micro Biosystems, Inc. (RPID)
  • Precipio, Inc. (PRPO)
  • Astrotech Corporation (ASTC)
SEER earnings history · SEER institutional & insider holders · SEER KPIs & operating metrics · SEER financials · SEER investor presentations & press releases · SEER SEC filings · SEER peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.